Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression

The overarching goal of the present study is to evaluate the effect of a subanesthetic dose of ketamine 24 hours post-injection on resting-state functional connectivity, cognitive control, and reward learning.

Topic Depression
Compound Ketamine
Country United States of America
Visit trial
Status Recruiting
Results Published
Start date 17 August 2020
End date 01 August 2023
Design Open
Type Observational
Participants 60
Sex All
Age 18- 64
Therapy No

Trial Details

Major Depressive Disorder (MDD) participants with treatment-resistant depression (TRD) will be recruited from McLean's Ketamine clinic. Suitability for Ketamine treatment will be determined as typically done by the service - through evaluation by the clinicians on the staff of the Ketamine Service who perform psychiatric consultations and assessments for Ketamine suitability. Potential subjects will be informed about the study only after they have received a positive consultation at the clinic and have already agreed to receive the treatment. This study consists of a set of questionnaires, urine drug screen, and electroencephalogram (EEG) recordings.

Trial Number NCT04239963

Sponsors & Collaborators

Mclean Hospital
McLean Hospital is a psychiatric hospital in Belmont, Massachusetts. The hospital maintains the world's largest neuroscientific and psychiatric research program in a private hospital.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.